AHIA
AVEO

Andrew Hill Investment Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Andrew Hill Investment Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed – – 229
2021
Q4 		$0 Buy
+10
New +$62 ﹤0.01% 227

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Andrew Hill Investment Advisors's AVEO Position: Q1 2022 in Review

Andrew Hill Investment Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2022, closing a stake of 10 shares.

Andrew Hill Investment Advisors first reported a position in AVEO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 58 funds tracked by Wall St. Rank hold AVEO as of Q1 2022.

  • Andrew Hill Investment Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Andrew Hill Investment Advisors sold 10 AVEO Pharmaceuticals, Inc. shares in Q1 2022.
  • Andrew Hill Investment Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Andrew Hill Investment Advisors's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q4 2021.
  • 58 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2022.

Based on Andrew Hill Investment Advisors's 13F filing for Q1 2022, filed 11 May 2022.